Riesgo cardiovascular en artritis reumatoidea: revisión narrativa
Resumen
La artritis reumatoide (AR) es una enfermedad autoinmune crónica con compromiso especialmente articular que se relaciona con un aumento exponencial del riesgo cardiovascular (RCV). La actividad de la enfermedad se puede medir con escalas clinimétricas, como el Disease Activity Score 28 (DAS 28) y el RCV con escalas como la de Framingham y SCORE, disponibles como aplicación electrónica para dispositivos móviles. El adecuado control de la enfermedad disminuye el RCV; lograr este objetivo requiere la participación importante de los centros de salud de primer nivel, para quienes se presenta en esta revisión una aproximación práctica sobre aspectos concretos de tratamiento de la AR y enfoque del RCV.Descargas
Disciplinas:
Internal Medicine, CardiologyLenguajes:
esReferencias bibliográficas
(1) Klarenbeek NB, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart CF. Recent advances in the management of rheumatoid arthritis. BMJ. 2010;21(341):c6942.
(2) Machado-Alba JE, Ruiz AF, Moralesca DAM. The epidemiology of rheumatoid arthritis in a cohort of Colombian patients. Rev Colomb Reumatol. 2015;22(3):148–52.
(3) Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–31.
(4) Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25):2889–934.
(5) Amaya-Amaya J, Sarmiento-Monroy JC, Mantilla R-D, Pineda-Tamayo R, Rojas-Villarraga A, Anaya J-M. Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunol Res. 2013 Jul;56(2-3):267–86.
(6) Wong BW, Meredith A, Lin D, McManus BM. The biological role of inflammation in atherosclerosis. Can J Cardiol. 2012; 28(6): 631–41.
(7) Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20.
(8) Grad E, Danenberg HD. C-reactive protein and atherothrombosis: Cause or effect?. Blood Rev. 2013 ;27(1):23–9.
(9) Soubrier M, Barber Chamoux N, Tatar Z, Couderc M, Dubost J-J, Mathieu S. Cardiovascular risk in rheumatoid arthritis. Joint Bone Spine. 2014;81(4):298–302.
(10) Peters MJL, Voskuyl AE, Sattar N, Dijkmans BAC, Smulders YM, Nurmohamed MT. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int J Clin Pract. 2010;64(10):1440–3.
(11) Chung W-S, Lin C-L, Peng C-L, Chen Y-F, Lu C-C, Sung F-C, et al. Rheumatoid arthritis and risk of acute myocardial infarction--a nationwide retrospective cohort study. Int J Cardiol. 2013;168(5):4750–4.
(12) Hollan I, Dessein PH, Ronda N, Wasko MC, Svenungsson E, Agewall S, et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev. 2015;14(10):952–69.
(13) Meune C, Touzé E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103(4):253–61.
(14) Corrao S, Argano C, Pistone G, Messina S, Calvo L, Perticone F. Rheumatoid arthritis affects left ventricular mass: Systematic review and meta-analysis. Eur J Intern Med. 2015;26(4):259–67.
(15) Lazzerini PE, Capecchi PL, Acampa M, Galeazzi M, Laghi-Pasini F. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev. 2014;13(9):936–44.
(16) Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6):929–34.
(17) Purcarea A, Sovaila S, Gheorghe A, Udrea G, Stoica V. Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis? J Med Life. 2014;7(4):461–7.
(18) Monk HL, Muller S, Mallen CD, Hider SL. Cardiovascular screening in rheumatoid arthritis: a cross-sectional primary care database study. BMC Fam Pract. 2013; 14:150.
(19) Bell C, Rowe IF. The recognition and assessment of cardiovascular risk in people with rheumatoid arthritis in primary care: a questionnaire-based study of general practitioners. Musculoskeletal Care. 2011;9(2):69–74.
(20) Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology. 2013;52(1):45–52.
(21) Faden G, Viapiana O, Fischetti F, Faganello G, Gatti D, Tarantini L, et al. Cardiovascular risk stratification and management of patients with rheumatoid arthritis in clinical practice: the “EPIDAURO registry.” Int J Cardiol. 2014;172(2):534–6.
(22) Crowson CS, Liao KP, Davis JM 3rd, Solomon DH, Matteson EL, Knutson KL, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166(4):622–8.e1.
(23) Sen D, González-Mayda M, Brasington RD Jr. Cardiovascular disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2014;40(1):27–49.
(24) Martín-Martínez MA, González-Juanatey C, Castañeda S, Llorca J, Ferraz-Amaro I, Fernández-Gutiérrez B, et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. Semin Arthritis Rheum. 2014;44(1):1–8.
(25) Gonzalez-Mayda M, Sen D, Brasington R. Rheumatoid arthritis and cardiac disease. Int J Clin Rheumtol. 2014;9(5):457–73.
(26) Tanasescu C, Jurcut C, Jurcut R, Ginghina C. Vascular disease in rheumatoid arthritis: from subclinical lesions to cardiovascular risk. [Internet] Eur J Intern Med. 2009 Jul;20(4):348–54.
(27) Giles JT. Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice. [Internet] Best Pract Res Clin Rheumatol. 2015 Aug;29(4-5):597–613.
(28) Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70(1):8–14.
(29) Primdahl J, Clausen J, Hørslev-Petersen K. Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann Rheum Dis. 2013;72(11):1771–6.
(30) Muñoz OM, García A, Fernández D, Higuera A, Ruiz Á, Aschner P. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años. Acta Médica Colomb. 2014;39(S2):1-27.
(31) Muñoz OM, García ÁA, Fernández-Ávila D, Higuera A, Ruiz ÁJ, Aschner P, et al. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: evaluación del riesgo cardiovascular. Revista Colombiana de Cardiología. 2015 Nov;22(6):263–9.
(32) European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M-R, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818.
(33) Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82.
(34) González-Gay MA, González-Juanatey C. Cardiovascular disease in rheumatoid arthritis. Importance and clinical management. Reumatol Clin. 2009;5(3):95–7.
(35) Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.
(36) Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745–57.
(37) Grillo Ardila CF, Torres M, Quintana G. Development of Clinical Practice Guideline for the early detection, Diagnosis and treatment of patients with rheumatoid arthritis and juvenile idiopathic arthritis. Revista Colombiana de Reumatología. Asociación Colombiana de Reumatología; 2013;20(2):77–9.
(38) Quintana G, Grillo Ardila CF, Mendez P, Vallejo MT, et al. Guía de práctica clínica para la detección temprana, diagnóstico y tratamiento de la artritis reumatoide. Guía para profesionales de la salud. 2014;12(5): 1-71
(39) Singh JA, Saag KG, Bridges SL, Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1–26
(40) Solomon D. H. et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010; 69(11): 1920–1925.
(41) Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med. 2013;126(8):730.e9–730.e17.
(42) Al-Aly Z, Pan H, Zeringue A, Xian H, McDonald JR, El-Achkar TM, et al. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res. 2011;157(1):10–8.
(43) Sandoo A, Kitas GD, Carroll D, Veldhuijzen van Zanten JJCS. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res Ther. 2012;14(3): 117.
(44) Provan SA, Berg IJ, Hammer HB, Mathiessen A, Kvien TK, Semb AG. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tocilizumab. PLoS One. 2015;10(6): e0130709.
(45) Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res. 2012;64(9):1282–91.
(46) Danninger K, Hoppe UC, Pieringer H. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis? Int J Rheum Dis. 2014;17(6):606–11.
(47) van Breukelen-van der Stoep DF, Klop B, van Zeben D, Hazes JMW, Castro Cabezas M. Cardiovascular risk in rheumatoid arthritis: how to lower the risk? Atherosclerosis. 2013;231(1):163–72.
.png)
